Alfred Gilman - Regeneron Pharmaceuticals Independent Director

<div class='circular--portrait' style='background:#0D8ECF;color: white;font-size:4em;padding-top: 15px;;'>RE</div>
REGN -- USA Stock  

Earning Report: February 6, 2020  

  Director
Dr. Alfred G. Gilman M.D. Ph.D. is an Independent Director of Regeneron Pharmaceuticals Inc. since July 1990. Dr. Gilman is a cofounder of the Company was a nonemployee Director of the Company since July 1990. Dr. Gilman is a Regental Professor Emeritus of Pharmacology at The University of Texas Southwestern Medical Center at Dallas. He was the chief scientific officer of the Cancer Prevention and Research Institute of Texas from 2009 to 2012. He previously served as executive vice president for academic affairs and provost of The University of Texas Southwestern Medical Center at Dallas dean of The University of Texas Southwestern Medical School and professor of pharmacology at The University of Texas Southwestern Medical Center. Dr. Gilman is a member of the National Academy of Sciences and he received the Nobel Prize for Physiology or Medicine in 1994. He is one of the inaugural fellows of the American Association of Cancer Research
Age: 72  Director Since 1990  Ph.D    
914 847-7000  www.regeneron.com
Gilman distinguished scientific and academic background, including his receipt of the Nobel Prize for Physiology or Medicine in 1994, and his leadership positions at the Cancer Prevention and Research Institute of Texas, The University of Texas Southwestern Medical Center at Dallas, and The University of Texas Southwestern Medical School, together with his extensive experience as a director of the Company and of a leading pharmaceutical company, led to the board decision to nominate Dr. Gilman for reelection to the board.

Alfred Gilman Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 23.16 % which means that it generated profit of $23.16 on every $100 spent on asset. This is very large. Similarly, it shows return on stockholders equity (ROE) of 31.86 % meaning that it created $31.86 on every $100 dollars invested by stockholders.
The company currently holds 738 M in liabilities with Debt to Equity (D/E) ratio of 7.0 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Regeneron Pharmaceuticals has Current Ratio of 3.95 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

William YoungVertex Pharmaceuticals Incorpor
2014
Elaine UllianVertex Pharmaceuticals Incorpor
2011
Anupam PuriDr Reddys Laboratories Ltd
2002
Lloyd CarneyVertex Pharmaceuticals Incorpor
2019
Theodore SamuelstoPerrigo Company Plc
2017
Frank DAmelioZoetis
2016
Robert ScullyZoetis
2013
David AltshulerVertex Pharmaceuticals Incorpor
2015
Omkar GoswamiDr Reddys Laboratories Ltd
2000
Linda RhodesZoetis
2017
Gary CohenPerrigo Company Plc
2009
Michael TrimbleOrigin Agritech Limited
2006
Kalpana MorpariaDr Reddys Laboratories Ltd
2007
Yingqi XiaOrigin Agritech Limited
2010
Min TangOrigin Agritech Limited
2009
William SteereZoetis
2013
Herman MorrisPerrigo Company Plc
1999
Paul BisaroZoetis
2015
J MoreauDr Reddys Laboratories Ltd
2007
Shikha SharmaDr Reddys Laboratories Ltd
2019
Sridar IyengarDr Reddys Laboratories Ltd
2011

Entity Summary

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 7674 people.Regeneron Pharmaceuticals (REGN) is traded on BATS Exchange in USA and employs 7,674 people.

Regeneron Pharmaceuticals Leadership Team

Charles Baker, Independent Director
Joseph Goldstein, Independent Director
Anthony Coles, Independent Director
George Sing, Independent Director
Peter Powchik, Senior Vice President - Clinical Development
Jay Markowitz, Senior Vice President - Portfolio Management
Robert Terifay, Sr. VP of Commercial
Robert Landry, CFO and Sr. VP of Fin.
Michael Brown, Independent Director
Christine Poon, Independent Director
Neil Stahl, Executive VP of RandD
Marion McCourt, Senior Vice President and Head of Commercial
George Yancopoulos, Chief Scientific Officer and President - Regeneron Laboratories, Director
Huda Zoghbi, Director
Bonnie Bassler, Director
Joseph LaRosa, Senior Vice President General Counsel, Secretary
Daniel Plew, Senior Vice President General Manager - Industrial Operations and Product Supply
Leonard Schleifer, President CEO, Director
Alfred Gilman, Independent Director
Roy Vagelos, Chairman of the Board
Michael Aberman, Vice President - Strategy
Manisha Narasimhan, IR Contact
Douglas McCorkle, Vice President Controller, Assistant Treasurer
Marc TessierLavigne, Independent Director
Christopher Fenimore, Vice President Controller
Arthur Ryan, Independent Director

Stock Performance Indicators

Current Sentiment - REGN

Regeneron Pharmaceuticals Investor Sentiment

Majority of Macroaxis users are at this time bullish on Regeneron Pharmaceuticals. What is your perspective on investing in Regeneron Pharmaceuticals? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Currently Active Assets on Macroaxis

USRT   
Purchased few shares of
a day ago
Traded for 55.68
IJR   
Purchased few shares of
a day ago
Traded for 85.37
IJH   
Purchased one share of
a day ago
Traded for 209.15
IVV   
Purchased one share of
a day ago
Traded for 333.5
IDEV   
Purchased few shares of
a day ago
Traded for 59.01
Additionally take a look at Your Equity Center. Please also try Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.